Fosun Tourism’s post-Covid holiday fizzles
The resort unit of one of China’s leading conglomerates posted modest growth in the first quarter, as its broader outlook was clouded by debt issues at its parent Key Takeaways:…
Fosun Tourism at crossroads as parent shops its two major assets
Fosun International is reportedly looking to sell some or all of its tourism unit’s Atlantis Sanya mega-resort, as well as a stake in the unit’s Club Med resort chain Key…
NEWS WRAP: Lanvin business stagnates in 2023
The unit of Chinese conglomerate Fosun reported its revenue rose just 1% last year as the global luxury goods market stalled By Teri Yu Luxury fashion brand operator Lanvin…
Fosun Tourism embarks on new journey with departure of big-name director
Henri Giscard d’Estaing has left the board of Fosun Tourism, which is refocusing on China and Southeast Asia, to ‘devote additional time and attention’ to his role leading Club Med…
Fosun Tourism rides Club Med rebound into bumper profits
The global resort operator’s business volume rose 24% in the first half of the year, while its profit more than doubled Key Takeaways: Fosun Tourism’s business volume rose 24% in…
CHINA BULLETIN: Top U.S. Diplomat, Banker Plot First Post-Covid China Trips
In this week’s issue Antony Blinken hopes to call on Beijing, May Day travelers return to the road, and Luckin’s disgraced co-founders return to the coffee business. On a scale of 1 to 100, we give the week a 60 for offshore-listed China stocks.
Lanvin inaugural results: Belle of the ball, or luxury runner-up?
The owner of several high-end fashion brands touted record sales and margin improvement for 2022, but revenue fell short of its earlier projection and its net loss widened Key Takeaways:…
Recent Articles
RELATED ARTICLES
-
Fosun Tourism at crossroads as parent shops its two major assets
1992.HK 0656.HK
-
Fosun Tourism embarks on new journey with departure of big-name director
1992.HK
-
Fosun Tourism rides Club Med rebound into bumper profits
1992.HK
-
Debt pressures cast cloud over Fosun Pharma results
2196.HK 600196.SHG
- CHINA BULLETIN: Next Stop, Deflation
-
Tongcheng flies high on post-Covid domestic travel boom
0780.HK
-
Fosun Pharma, CanSino take different paths as Covid lift fade
2196.HK 6185.HK
